EOLS - Evolus, Inc.
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has entered into an option agreement with a privately held company developing a novel, procedure-based, sustained-release injectable treatment for hair restoration.The agreement advances Evolus' business development strategy by adding a potential new category that is complementary to its existing injec.
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
LOS ANGELES--(BUSINESS WIRE)---- $EOLS--EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law.
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The U.S. Food and Drug Administration's Office of Prescription Drug Promotion in September issued a warning letter to Evolus Inc. (NASDAQ:EOLS) regarding misleading Instagram promotional posts for its injectable prescription drug, Jeuveau (prabotulinumtoxinA-xvfs).
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the launch of Wings by Evolus, a new charitable platform designed to bring together aesthetic practices, providers, and patients to support organizations and causes that positively impact their communities. The first Wings by Evolus initiative will launch in October in recognition of Breast Cancer Awareness M.
BlackRock Inc. acquired a new stake in shares of Evolus, Inc. (NASDAQ: EOLS) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 4,840,828 shares of the company's stock, valued at approximately $33,595,000. BlackRock Inc. owned approximately 7.35% of Evolus as of its most recent SEC filing.
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture P
The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Evolus, Inc. (NASDAQ: EOLS - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $8.82 and last traded at $8.78, with a volume of 1320192 shares. The stock had previously closed at $8.39. Wall Street Analysts Forecast Growth EOLS has been the subject
Assenagon Asset Management S.A. lifted its holdings in Evolus, Inc. (NASDAQ: EOLS) by 51.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 908,180 shares of the company's stock after acquiring an additional 310,035 shares during the period. Assenagon Asset
The average of price targets set by Wall Street analysts indicates a potential upside of 106.1% in Evolus (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Evolus is evolving into a multi-product aesthetics platform, leveraging its distribution network and loyalty ecosystem to drive operating leverage and recurring revenue. Q2 2026 results showed 21% revenue growth, positive adjusted EBITDA, and raised guidance, with management projecting 2028 revenue of $450M–$500M and EBITDA margins of 13–15%. Evolus trades at a forward EV/Sales of 1.86, a 50% discount to sector median, but requires margin expansion to justify valuation as it transitions from single-product to platform economics.
Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript
Evolus, Inc. (EOLS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.24 per share a year ago.
Evolus NASDAQ: EOLS reported second-quarter revenue growth of 21% and raised the lower end of its full-year 2026 revenue outlook, citing market-share gains in neurotoxins and hyaluronic acid injectable gels, continued customer adoption of its portfolio and expanding international operations.
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the second quarter ended June 30, 2026. “The increasing momentum of our portfolio focus has resulted in Evolus gaining significant share across injectable aesthetics during the second quarter, supported by double-digit growth for Jeuveau® and accelerating adoption of Evolysse®,” said.